Indian pharma leaving generics era behind: Kulkarni
Synopsis Indian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. Companies are investing in advanced research
Synopsis Indian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. Companies are investing in advanced research and development.
Global regulatory changes favor Indian players. The market is not yet fully recognizing this innovation pivot and the quality of talent driving it. GLP-1 drugs
and supply chain diversification also present substantial growth potential.
The BriefWire